

PRESS RELEASE

WILEX AG successfully completes change of name to Heidelberg Pharma AG

- Entry in the commercial register made on 18 October 2017
- Subsidiary Heidelberg Pharma GmbH to be renamed Heidelberg Pharma Research GmbH

Ladenburg, Germany, 19 October 2017 – Heidelberg Pharma – formerly WILEX AG - (ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6) today announced that its relocation from Munich to Ladenburg and its name change from WILEX AG to Heidelberg Pharma AG have been successfully completed with its entry in the Mannheim commercial register on 18 October 2017. The Company's shares will continue to be listed on the Regulated Market of the Frankfurt Stock Exchange's Prime Standard under their old ISIN, German securities identification code (WKN) and symbol. Its subsidiary Heidelberg Pharma GmbH is now doing business as Heidelberg Pharma Research GmbH. The Annual General Meeting on 20 July 2017 adopted a resolution to change the name of the Company and relocate its headquarters from Munich to Ladenburg.

“Our Company's core business has been driven by the research and development activities of our subsidiary Heidelberg Pharma GmbH for some time. The renaming and relocation of the Company are part of our strategic realignment and the refinement of our business model,” commented Dr. Jan Schmidt-Brand, CEO and CFO of Heidelberg Pharma AG. “In keeping with these changes, the Heidelberg Pharma companies now have a uniform, updated corporate identity, including a new corporate website.”

Heidelberg Pharma is working to enhance its value by developing and licensing the proprietary ATAC technology platform, entering into project partnerships and building a proprietary ATAC portfolio. Clinical development of the first proprietary product candidate HDP-101 in multiple myeloma is expected to begin at the end of 2018.

The Company's new website can be found at www.heidelberg-pharma.com.

About Heidelberg Pharma

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs, as well as in third-party collaborations, to create a variety of ATAC candidates. The proprietary lead candidate is HDP-101, a BCMA ATAC for multiple myeloma. The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON® and

REDECTANE[®], while RENCAREX[®] is available for out-licensing and further development. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg-pharma.com.

Contact

Heidelberg Pharma AG
Sylvia Wimmer
Tel.: +49 89 41 31 38-29
Email: [investors\[at\]hdpharma.com](mailto:investors[at]hdpharma.com)
Schriesheimer Str. 101, 68526 Ladenburg

IR/PR support

MC Services AG
Katja Arnold (CIRO)
Managing Director & Partner
Tel.: +49 89 210 228-40
Email: [katja.arnold\[at\]mc-services.eu](mailto:katja.arnold[at]mc-services.eu)

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.